Ebos GroupASX:EBO +0.66%77 Days Payable is 72.19 as of Dec. 2025, which is 10% above its 10-year median of 65.74. GuruFocus rates ASX:EBO with a GF Score™ of 77/100 and a GF Value™ of A$32.52 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 115 Medical Distribution companies, Ebos Group ranks worse than 54.78% on this metric.
Ebos Group's average Accounts Payable for the
six
months ended in Dec. 2025 was A$2,352 Mil. Ebos Group's Cost of Goods Sold for the
six
months ended in Dec. 2025 was A$5,947 Mil.
Hence, Ebos Group's Days Payable for the
six
months ended in Dec. 2025 was 72.19.
The historical rank and industry rank for Ebos Group's Days Payable or its related term are showing as below:
ASX:EBO'
s Days Payable Range Over the Past 10 Years
Min: 57.26 Med: 65.74 Max: 74.62
Current: 74.62
During the past 13 years, Ebos Group's highest Days Payable was 74.62. The lowest was 57.26. And the median was 65.74.
ASX:EBO's Days Payable is ranked worse than 54.78% of 115
companies
in the Medical Distribution industry
Industry Median: 79.81
vs ASX:EBO: 74.62
Ebos Group's Days Payable
declined
from Dec. 2024 (74.13) to Dec. 2025 (72.19).
It may suggest that Ebos Groupaccelerated paying its suppliers.
Ebos Group Days Payable Related Terms
Ebos Group Days Payable Historical Data
* Premium members only.
The historical data trend for Ebos Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Ebos Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Ebos Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ebos Group's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group (ASX:EBO) has a Days Payable of 72.19 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ebos Group and its competitors. This is 10% above median its historical median of 65.74. Over the past decade, Ebos Group's Days Payable has ranged from 57.26 to 74.62. According to the industry distribution chart, Ebos Group ranks #63 out of 115 companies in the Medical Distribution industry, placing it in the top 54.8%.
Is Ebos Group's Days Payable too high?
Ebos Group's current Days Payable of 72.19 is 10% above median its 10-year median of 65.74. Over the past 10 years, this metric has ranged from a low of 57.26 to a high of 74.62. The Medical Distribution industry median Days Payable is 79.81. Ebos Group's value of 72.19 is 9.5% below this industry median. Based on the distribution chart, Ebos Group ranks #63 out of 115 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ebos Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Days Payable compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #63 out of 115 companies for Days Payable. This places Ebos Group in the lower half of its industry. The industry median Days Payable is 79.81. Ebos Group's value of 72.19 is 9.5% below this benchmark. Historically, Ebos Group's own Days Payable has ranged from 57.26 to 74.62 over the past decade. While the company's 10-year median is 65.74 vs. the industry median of 79.81, Ebos Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.81, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current Days Payable of 72.19 is 9.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median Days Payable is 79.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current Days Payable is 72.19, which is 10% above median its own 10-year median of 65.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$32.52, compared to a current price of A$16.87 — trading 48.1% below its estimated fair value. The current Days Payable is 72.19, which is 10% above median its 10-year median of 65.74 and 9.5% below the Medical Distribution industry median of 79.81. Ebos Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current Days Payable is 72.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$16.87 is trading 48.1% below its estimated GF Value™ of A$32.52.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for ASX:EBO:
Days Payable: 72.19 (10% above median its 10-year median of 65.74)
GF Value™: A$32.52 vs. price of A$16.87 (48.1% below fair value)
Industry Position: 9.5% below the Medical Distribution median (#63 of 115)
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
77GF Score
Get the complete analysis for ASX:EBO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
